PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 14, 2012
PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors
June 6, 2012 / Pharmacogenomics Reporter - FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter - Roche, BMS Hope to Improve Outcomes in BRAF-Mutated Melanoma Patients with Dual Treatment Regimen
June 8, 2011 / Pharmacogenomics Reporter - CHMP Recommends EU Approval of Roche PGx Drug Zelboraf
December 21, 2011 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter